SFJ Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.sfj-pharma.com
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- SFJ Pharmaceuticals, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT05162131
- Locations
- 🇨🇳
Beijing Friendship Hospital, Tongzhou, Beijing, China
Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure
Phase 3
Completed
- Conditions
- HemorrhageUrgent SurgeryInvasive Procedure
- Interventions
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- SFJ Pharmaceuticals, Inc.
- Target Recruit Count
- 226
- Registration Number
- NCT04286438
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇳🇱Medisch Spectrum Twente, Enschede, Overijssel, Netherlands
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: Placebo (0.9% Sodium chloride) infusion
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- SFJ Pharmaceuticals, Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT04122170
- Locations
- 🇺🇸
Remington-Davis, Inc., Columbus, Ohio, United States
🇨🇦BioPharma Services Inc., Toronto, Ontario, Canada
🇺🇸PPD Development, LP, Orlando, Florida, United States
Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: Placebo - Sodium ChlorideDrug: PB2452 Infusion
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- SFJ Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03928353
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PB2452 InfusionDrug: Placebo - Sodium Chloride
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- SFJ Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT03492385
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath